

### CLAIMS

1. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:
  - i a 5-substituted pyrazolo [4,3-d]pyrimidine-7-one as disclosed in European patent application 0201188;
  - ii a griseolic acid derivative as disclosed in European patent applications nos 0214708 and 0319050;
  - iii a 2-phenylpurinone derivative as disclosed in European patent application 0293063;
  - iv a phenylpyridone derivative as disclosed in European patent application 0347027;
  - v a fused pyrimidine derivative as disclosed in European patent application 0347146;
  - vi a condensed pyrimidine derivative as disclosed in European patent application 0349239;
  - vii a pyrimidopyrimidine derivative as disclosed in European patent application 0351058;
  - viii a purine compound as disclosed in European patent application 0352960;
  - ix a quinazolinone derivative as disclosed in European patent application 0371731;
  - x a phenylpyrimidone derivative as disclosed in European patent application 0395328;
  - xi an imidazoquinoxalinone derivative or its aza analogue as disclosed in European patent application 0400583;
  - xii a phenylpyrimidone derivative as disclosed in European patent application 0400799;
  - xiii a phenylpyridone derivative as disclosed in European patent application 0428268;

- xiv a pyrimidopyrimidine derivative as disclosed in European patent 0442204;
  - xv a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
  - xvi a 4,5-dihydro-4-oxo-pyrrolo[1,2-a]quinoxaline derivative or its aza analogue as disclosed in European patent application 0584487;
  - xvii a polycyclic guanine derivative as disclosed in International patent application WO91/19717;
  - xviii a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
  - xix a 2-benzyl-polycyclic guanine derivative as disclosed in International patent application WO 94/19351;
  - xx a quinazoline derivative as disclosed in US patent 4060615
  - xxi a 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one as disclosed in US patent 5294612
  - xxii a benzimidazole as disclosed in Japanese patent application 5-222000; or
  - xxiii a cycloheptimidazole as disclosed in European Journal of Pharmacology, 251, (1994), 1.
  - xxiv a N-containing heterocycle as disclosed in International patent application WO94/22855.
2. The use of a compound as claimed in claim 1 wherein said compound is:
- a 4-aminoquinazoline derivative as disclosed in European patent application 0579496;
  - a nitrogenous heterocyclic compound as disclosed in International patent application WO93/07124;
  - a 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one as disclosed in US patent 5294612 or
  - a N-containing heterocycle as disclosed in International patent application WO94/22855.
3. The use of a compound as claimed in claim 1 wherein said compound is:
- 1,3-dimethyl-5-benzylpyrazolo[4,3-d]pyrimidine-7-one;
  - 2-(2-propoxyphenyl)-6-purinone;
  - 6-(2-propoxyphenyl)-1,2-dihydro-2-oxopyridine-3-carboxamide;

2-(2-propoxyphenyl)pyrido[2,3-d]pyrimid-4(3H)-one;  
 7-methylthio-4-oxo-2-(2-propoxyphenyl)-3,4-dihydropyrimido[4,5-d]pyrimidine;  
 6-hydroxy-2-(2-propoxyphenyl)pyrimidine-4-carboxamide;  
 1-ethyl-3-methylimidazo[1,5a]quinoxalin-4(5H)-one;  
 4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline;  
 5-ethyl-8-[3-(N-cyclohexyl-N-methylcarbamoyl)-propyloxy]-4,5-dihydro-4-oxo-pyrido[3,2-e]pyrrolo[1,2-a]pyrazine;  
 5'-methyl-3'-(phenylmethyl)-spiro[cyclopentane-1,7'(8'H)-(3'H)-imidazo[2,1-b]purin]4'(5'H)-one  
 1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl]piperidine-4-carboxylic acid;  
 (6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one;  
 1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimid-4-one;  
 1-cyclopentyl-3-methyl-6-(4-pyridyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimid-4-one;  
 2-butyl-1-(2-chlorobenzyl)6-ethoxycarbonylbenzimidazole;  
 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline;  
 or 2-phenyl-8-ethoxycycloheptimidazole.

4. The use of a compound as claimed in claim 3 where said compound is:  
 4-phenylmethylamino-6-chloro-2-(1-imidazoloyl)quinazoline;  
 1-[6-chloro-4-(3,4-methylenedioxybenzyl)aminoquinazolin-2-yl]piperidine-4-carboxylic acid;  
 (6aR,9aS)-2-(4-trifluoromethylphenyl)methyl-5-methyl-3,4,5,6a,7,8,9,9a-octahydrocyclopent[4,5]imidazo[2,1-b]purin-4-one;  
 1-tert-butyl-3-phenylmethyl-6-(4-pyridyl)pyrazolo[3,4-d]pyrimid-4-one;  
 1-cyclopentyl-3-methyl-6-(4-pyridyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimid-4-one;  
 or  
 2-(4-carboxypiperidino)-4-(3,4-methylenedioxybenzyl)amino-6-nitroquinazoline;

5. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the treatment of erectile dysfunction in a male animal, including man, wherein said compound is:

xxv a pyrazolopyrimidine derivative as disclosed in European patent application 0636626;

xxvi a 4-aminopyrimidine derivative as disclosed in European patent application 0640599;

xxvii a imidazoquinazoline derivative as disclosed in International patent application WO95/06648;

xxviii an anthranilic acid derivative as disclosed in International patent application WO95/18097;

xxix a 4-aminoquinazoline derivative as disclosed in US patent 5436233;

xxx a tetracyclic derivative as disclosed in International patent application WO95/19978;

xxxi a imidazoquinazoline derivative as disclosed in European patent application 0668280; or

xxxii a quinazoline compound as disclosed in European patent application 0669324.

6. The use of a compound which is a selective cGMP PDE inhibitor for the manufacture of a medicament for the curative or prophylactic treatment of female sexual dysfunction, premature labour or dysmenorrhea, wherein said compound is a compound as previously claimed in any one of claims 1 to 5 for use in the treatment of erectile dysfunction in a male.

7. A method for the treatment of erectile dysfunction in a male animal or female sexual dysfunction, premature labour or dysmenorrhea, which comprises administering an effective amount of a compound which is a selective cGMP PDE inhibitor as previously claimed in any one of claims 1 to 5.